DANAHER CORP /DE/(DHR)— Stock Profile, AI Score & Financials
Technology · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
DANAHER CORP /DE/ (DHR) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. 13F Pro's AI-powered ranking engine scores DHR at 64.8/100 on a 32-signal composite quality model, placing it at rank #521 of 2,961 stocks — the top 25% of the AI-ranked universe. DHR scores in the top quartile across revenue scale (94.0), profitability (76.3), free cash flow (75.2). Areas of concern include revenue growth (35.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), DANAHER CORP /DE/ reports quarterly revenue of $6.3B, net income of $870.0M, an operating margin of 18.0%. Top institutional holders of DHR by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, FMR, based on the most recent SEC filings. DHR trades on the NYSE exchange and files with the SEC under CIK 313616. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DHR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DANAHER CORP /DE/ directly from SEC EDGAR.
AI Quality Score
64.8/100
AI Rank
#521
Revenue
$6.3B
Net Income
$870.0M
Free Cash Flow
$1.3B
Operating Margin
18.0%
DHR key financials by period
DANAHER CORP /DE/ reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$24.6B
$3.6B
19.1%
FY 2024
10-K
$23.9B
$3.9B
20.4%
FY 2023
10-K
$23.9B
$4.8B
21.8%
FY 2022
10-K
$26.6B
$7.2B
28.3%
FY 2021
10-K
$24.8B
$6.4B
25.7%
FY 2020
10-K
$22.3B
$3.6B
19.0%
Institutions holding DHR
Institutional investors reporting a position in DANAHER CORP /DE/ on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-21 — Q2 FY2026 (quarter ended June 26, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q2 revenue grew 5.5% YoY to $6.3B, driven by 3.0% core sales growth and the Masimo acquisition; operating margin expanded 520 bps to 18.0% despite $74M in acquisition-related charges.
Biggest Revenue Drivers
Diagnostics$2.5B+7.0% YoY
Increased by Masimo Acquisition contribution and higher clinical diagnostics demand, partially offset by lower respiratory test sales.
Biotechnology$1.9B+4.0% YoY
Increased core sales driven by higher consumables and equipment sales in bioprocessing and discovery and medical businesses.
Biggest Revenue Drivers
Total revenue: $6.3B+5.5% YoY
Diagnostics$2.5B+7.0% YoY
Increased by Masimo Acquisition contribution and higher clinical diagnostics demand, partially offset by lower respiratory test sales.
Biotechnology$1.9B+4.0% YoY
Increased core sales driven by higher consumables and equipment sales in bioprocessing and discovery and medical businesses.
Life Sciences$1.9B+5.5% YoY
Increased core sales primarily driven by higher consumables demand and to a lesser extent higher equipment demand, particularly in filtration and life science instruments.
Largest Expense Items
Cost of sales$2.7B+9.9% YoY
Increased primarily due to higher sales volumes, acquired businesses, and $46M fair value adjustment to Masimo inventory.
Selling, general and administrative expenses$2.1B-12.2% YoY
Decreased primarily due to absence of $432M trade name impairment charge from Q2 2025, partially offset by Masimo acquisition-related costs and transaction costs of $62M.
Research and development expenses$412M+2.2% YoY
Increased with higher sales, but decreased as percentage of sales to 6.6%.
Margins: Operating margin expanded 520 bps to 18.0% in Q2 2026 from 12.8% in Q2 2025, primarily due to the absence of the $432M Life Sciences trade name impairment recorded in the prior year. Gross profit margin declined 170 bps to 57.6% due to product mix and the $46M inventory fair value adjustment related to Masimo, partially offset by operating leverage improvements.
Watch Items from the Filing
Masimo Acquisition integration: $9.8B acquisition closed June 10, 2026; preliminarily recorded $5.0B goodwill with ongoing measurement-period adjustments for fair value allocations and $74M nonrecurring charges in Q2.
Diagnostics segment respiratory testing dependency: Lower respiratory season in H1 2026 drove core sales decline of 1.0% YoY; future results depend on uncontrollable severity levels of influenza.
Foreign currency headwind: FX translation gained 1.0% and 2.0% to Q2 and H1 sales respectively; stronger U.S. dollar relative to euro and other currencies would adversely impact future sales.
China market softness: Core sales declined in Diagnostics and Biotechnology segments due to volume-based procurement program pricing pressures and healthcare reimbursement changes, though moderating.
Masimo litigation contingencies: Inherited $634M jury verdict from Apple patent litigation pending final judgment; multiple other legal proceedings (DOJ investigation, Kiani employment litigation, Willow arbitration) with uncertain outcomes.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
